𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Risedronate and Pamidronate Treatment in the Clinical Management of Patients with Severe Paget’s Disease of Bone and Acquired Resistance to Bisphosphonates

✍ Scribed by D. Rendina; G. Mossetti; R. Viceconti; M. Sorrentino; V. Nunziata

Publisher
Springer
Year
2004
Tongue
English
Weight
149 KB
Volume
75
Category
Article
ISSN
1432-0827

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who